It’s still early days, but the first set of data on Amgen, Inc.’s bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule, AMG 133, suggest it could gain an advantage on the market with its efficacy, durability and less frequent dosing in treating obesity than competing drugs.
Amgen presented data for AMG 133 on 3 December at the World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease...